Both Novo Nordisk (NYSE:NVO) and Sanofi (NYSE:SNY) said yesterday that they won FDA approval for pre-filled pens with drug combinations indicated for adults with Type II diabetes.
Paris-based Sanofi’s Soliqua 100/33 is an injectable medicine composed of 2 diabetes drugs – insulin glargine and lixisenatide. The drug is approved for adults with Type II diabetes not controlled with less than 60 units daily of long-acting basal insulin or lixisenatide. The pre-filled pen will be available in U.S. retail pharmacies in January, according to Sanofi.
Get the full story at our sister site, Drug Delivery Business News
The post Novo Nordisk, Sanofi win FDA nods for diabetes drugs appeared first on MassDevice.